News brief­ing: Kite looks to ex­pand Yescar­ta fran­chise with new in­di­ca­tions; Tiny Lixte looks to up­list on Nas­daq

A lit­tle more than a month af­ter gain­ing their first OK for their sec­ond CAR-T, Gilead’s Kite is in hot pur­suit of an ex­pand­ed use for their pi­o­neer­ing Yescar­ta.

The Gilead sub­sidiary has filed for an ap­proval to mar­ket the CAR-T as a third-line ther­a­py for re­lapsed or re­frac­to­ry fol­lic­u­lar lym­phoma and mar­gin­al zone lym­phoma. Giv­en the FDA’s break­through ther­a­py des­ig­na­tion here, as well as Yescar­ta’s track record, and you have an odds-on suc­cess.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER